The Almac Group
and
Greenphire
announced that
Almac’s Clinical Technologies
business unit has formed an exclusive alliance with Greenphire to offer joint services relating to patient payment administration for clinical trials. This new service improves current methods of manual patient payment management and alleviates administrative burden on personnel in biopharmaceutical companies and Contract Research Organizations (CROs), allowing them to focus on more study-specific responsibilities.
Greenphire has worked with Almac to incorporate its ClinCard System, a patient payment management suite of technologies, with Almac’s IXRS® system, an integrated phone and web platform. This industry offering provides patients with direct and timely compensation via a branded debit card. After patients complete required study-related tasks and responsibilities (e.g., attending site visits), their debit card is automatically and immediately credited with the appropriate stipend or reimbursement amount.
The Almac-Greenphire alliance provides several benefits to biopharmaceutical companies. The integrated platform improves operational efficiency, decreases sponsor, site and CRO administrative burden, reduces payment administration costs and timelines, and increases site and patient satisfaction. Research indicates that compensation is one of several important factors that drive patient compliance and eagerness to participate in clinical trials.
Almac President, Jim Murphy comments on the alliance with Greenphire: “Our customers are increasingly looking to Almac to help them find ways of improving patient management and compliance during clinical trials. Partnering with Greenphire enhances Almac’s suite of patient-centric services by offering direct-to-patient payments to subjects enrolled in clinical trials. This new joint service allows Almac to more efficiently manage patient payments and tie them closely to key study milestones through our IXRS® technology.”
From Greenphire’s perspective, the strategic partnership with Almac establishes another integrated platform through which the ClinCard System delivers value to pharmaceutical, biotech, and medical device companies. Building on Greenphire’s prior integrations with leading web-based clinical platforms, the ClinCard System will be customized to deliver, track, and report patient payments through Almac’s existing IXRS® workflow. As an alternative to manual, paper-based payment management processes, the ClinCard System offers real-time, secure, and easily accessible patient stipend and reimbursement payments.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.